Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gansu Fuzheng Pharmaceutical Wins Drug Patent Battle

This article was originally published in PharmAsia News

Executive Summary

Gansu Fuzheng Pharmaceutical Technologies and Gansu Xinlanyao Pharmaceutical, which jointly produce Zhenqi Fuzheng Capsule, received a Lunar New Year gift from China's State FDA: the announcement that it has terminated Guizhou Xinbang Pharmaceutical's Zhenqi Fuzheng Capsule production effective from Dec. 31. The two Gansu firms have been offering the capsule since 1993 and secured China's intellectual property rights in 2003. However, Guizhou Xinbang managed to get national approval to produce its "concentrated" version of the drug in Guizhou and Sichuan in 2001. The Gansu partners fought for seven years to regain the protected status of the patented drug, a quest supported by Gansu province's government and drug administration. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel